Global pharmaceutical firm XBiotech will break ground in early 2024 on an expansion of its Austin campus. Designed by MOD Architecture, the 46,000-sf R&D center will catalyze the discovery and development of innovative biomedical therapies, as well as accelerating the commercialization of the company’s Natrunix rheumatology treatment. Wet laboratories for infectious disease research will foster the creation of new vaccines and medications to address emerging health challenges.
T. Gene Edwards is the general contractor for the project, which is slated for occupancy in late 2025. The construction of a subterranean parking garage will reduce the facility’s ecological impact by allowing the preservation of existing woodland. The 48-acre site also houses the company’s 46,000-sf headquarters which was completed in 2016.
| Organization | Project Role |
|---|---|
|
MOD Architecture
|
Architect
|
|
T. Gene Edwards
|
General Contractor
|
